The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...
Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...
1mon
Exclusive-US FDA Taps Merck Drugs With Blockbuster Sales Potential for National Priority Vouchers
Merck's cholesterol pill enlicitide decanoate and its cancer therapy sacituzumab tirumotecan, or sac-TMT, have been tapped for the Commissioner's National Priority Voucher program, potentially making ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
Germany’s Merck KGaA has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug ...
Merck has unveiled a groundbreaking cholesterol-lowering pill, enlicitide, which could transform treatment for millions of Americans struggling with high LDL cholesterol. The once-daily oral ...
Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...
Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...
Add Yahoo as a preferred source to see more of our stories on Google. A vial and syringe are seen in front of Merck logo in this illustration taken March 26, 2025. REUTERS/Dado Ruvic/Illustration Dec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results